Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Katja C WeiselChristof ScheidManola ZagoBritta BesemerElias Karl MaiMathias HaenelJan DuerigMarkus MunderHans-Walter LindemannAnja SeckingerChristina KunzAxel BennerDirk HoseAnna JauchHans SalwenderHartmut Goldschmidt

Published in: Blood cancer journal (2019)

Keyphrases

phase ii
multiple myeloma
high dose
clinical trial
low dose
open label
phase iii
placebo controlled
double blind
study protocol